论文部分内容阅读
目的评价依达拉奉联合丁苯酞治疗进展性卒中的临床疗效。方法发病在72h内的进展性卒中患者120例随机分为两组,每组60例。治疗组给予依达拉奉联合丁苯肽治疗;对照组单纯应用丁苯酞治疗。对两组患者进行美国国立卫生院卒中量表(NIHSS)评分及日常生活能力(BI)评分。结果治疗组与对照组NIHSS评分和BI评分在治疗后14d、1个月差异均有统计学意义(P<0.05)。结论应用依达拉奉联合丁苯酞治疗进展性卒中疗效优于单用丁苯酞。
Objective To evaluate the clinical efficacy of edaravone and butylphthalide in the treatment of advanced stroke. Methods A total of 120 patients with progressive stroke within 72 hours were randomly divided into two groups (n = 60 in each group). The treatment group was treated with edaravone combined with butyrene. The control group was treated with butylphthalide. The NIH Stroke Scale (NIHSS) score and daily living ability (BI) scores were compared between the two groups. Results NIHSS score and BI score of the treatment group and the control group were significantly different at 14 and 1 months after treatment (P <0.05). Conclusion Edaravone combined with butylphthalide is superior to butylphthalide alone in the treatment of advanced stroke.